The scientist’s investigation covers issues in Ovarian cancer, Cancer research, Genetics, Internal medicine and Serous fluid. His research in Ovarian cancer is mostly concerned with Ovarian carcinoma. His biological study spans a wide range of topics, including Uterine Neoplasm, DNA methylation, Transcriptome, Immune system and KRAS.
His research integrates issues of Gynecology and Oncology in his study of Internal medicine. His work is dedicated to discovering how Serous fluid, Uterine serous carcinoma are connected with Microsatellite instability, Endometrial intraepithelial neoplasia and ARID1A and other disciplines. His PARP inhibitor study integrates concerns from other disciplines, such as microRNA, Serous carcinoma, Frameshift mutation and Poly Polymerase Inhibitor.
Douglas A. Levine mostly deals with Ovarian cancer, Internal medicine, Oncology, Cancer research and Serous fluid. The concepts of his Ovarian cancer study are interwoven with issues in Single-nucleotide polymorphism, Surgery, Chemotherapy and Bioinformatics. Douglas A. Levine has researched Internal medicine in several fields, including Gastroenterology and Gynecology.
His work carried out in the field of Cancer research brings together such families of science as DNA methylation, KRAS and Epigenetics, microRNA, Gene. Gene is a primary field of his research addressed under Genetics. His Serous fluid research integrates issues from Ovarian carcinoma, Carcinoma, Serous carcinoma and Cystadenocarcinoma.
His primary scientific interests are in Internal medicine, Ovarian cancer, Cancer research, Oncology and Cancer. Douglas A. Levine interconnects Oophorectomy, Malignancy, Serous fluid and Gynecology in the investigation of issues within Ovarian cancer. Douglas A. Levine has included themes like Ovarian carcinoma, Cancer cell, Transcription factor, Organoid and Biomarker in his Serous fluid study.
His Cancer research research includes elements of Immune checkpoint, Immunotherapy, Olaparib, Talazoparib and Veliparib. The Oncology study combines topics in areas such as Odds ratio, Germline mutation, Hazard ratio, Breast cancer and Prostate cancer. His research investigates the link between Methylation and topics such as DNA methylation that cross with problems in microRNA.
Douglas A. Levine mainly investigates Cancer research, Cancer, Ovarian cancer, Internal medicine and Oncology. His Cancer research research incorporates elements of DNA methylation, SMARCA4, Oncogene, KRAS and microRNA. His DNA methylation research incorporates themes from Regulation of gene expression, Transforming growth factor beta, Signal transduction and Mutation rate.
His work on HMGA2 and Non-coding RNA as part of general microRNA study is frequently linked to BMPR2 and MEG3, therefore connecting diverse disciplines of science. His Ovarian cancer research focuses on subjects like Serous fluid, which are linked to Fallopian tube. His work deals with themes such as Breast cancer, Carcinoma and Cancer Etiology, which intersect with Oncology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Integrated genomic analyses of ovarian carcinoma
D. Bell;A. Berchuck;M. Birrer;J. Chien.
Integrated genomic characterization of endometrial carcinoma
Gad Getz;Stacey B. Gabriel;Kristian Cibulskis;Eric Lander.
Inferring tumour purity and stromal and immune cell admixture from expression data
Kosuke Yoshihara;Maria Shahmoradgoli;Emmanuel Martínez;Rahulsimham Vegesna.
Nature Communications (2013)
Absolute quantification of somatic DNA alterations in human cancer
Scott L Carter;Kristian Cibulskis;Elena Helman;Elena Helman;Aaron McKenna.
Nature Biotechnology (2012)
Pan-cancer analysis of whole genomes
Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart.
Rethinking ovarian cancer: recommendations for improving outcomes
Sebastian Vaughan;Jermaine I. Coward;Robert C. Bast;Andy Berchuck.
Nature Reviews Cancer (2011)
Evaluating cell lines as tumour models by comparison of genomic profiles
Silvia Domcke;Rileen Sinha;Douglas A. Levine;Chris Sander.
Nature Communications (2013)
Proteogenomic characterization of human colon and rectal cancer
Bing Zhang;Jing Wang;Xiaojing Wang;Jing Zhu.
Resistance to therapy caused by intragenic deletion in BRCA2
Stacey L. Edwards;Rachel Brough;Christopher J. Lord;Rachael Natrajan.
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.
Jianfang Liu;Tara Lichtenberg;Katherine A Hoadley;Laila M Poisson.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: